fda weight‑loss drug curbs
Hidden Price of Prescription Weight Loss Bites Rural Pharmacies
A 27% slowdown in prescription fulfillment could empty a rural pharmacy’s shelves of GLP-1 weight-loss drugs, leaving patients without treatment. The FDA’s recent proposal to pull semaglutide, tirzepatide and liraglutide from the 503B bulk compounding list tightens the supply chain that small pharmacies rely on, making stockouts more